Orthogonally Functionalized Nanoscale Micelles for Active Targeted Codelivery of Methotrexate and Mitomycin C with Synergistic Anticancer Effect

Li, Yang; Lin, Jun; Wu, Hongjie; Cen, Ying; Yuan, Conghui; Liu, Cheng; Wang, Shuang; Hou, Zhenqing; Dai, Lizong

doi:10.1021/mp5006068

Cited by 58 publications

(47 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…alekseeva et al polyamide dendrimers, 5 polymer nanogels, 6 nanostructured carriers composed of triglycerides and surfactants, 7 quantum dots, 8 polyethylene glycol (PEG)-phospholipid micelles, 9 and liposomes. 10,11 Most of these carriers have insufficient drugloading capacity.…”

mentioning

confidence: 99%

Liposomal formulation of a methotrexate lipophilic prodrug: assessment in tumor cells and mouse T-cell leukemic lymphoma

Алексеева¹,

Моисеева²,

Onishchenko³

et al. 2017

IJN

View full text Add to dashboard Cite

In a previous study, a formulation of methotrexate (MTX) incorporated in the lipid bilayer of 100-nm liposomes in the form of diglyceride ester (MTX-DG, lipophilic prodrug) was developed. In this study, first, the interactions of MTX-DG liposomes with various human and mouse tumor cell lines were studied using fluorescence techniques. The liposomes composed of egg phosphatidylcholine (PC)/yeast phosphatidylinositol/MTX-DG, 8:1:1 by mol, were labeled with fluorescent analogs of PC and MTX-DG. Carcinoma cells accumulated 5 times more MTX-DG liposomes than the empty liposomes. Studies on inhibitors of liposome uptake and processing by cells demonstrated that the formulation used multiple mechanisms to deliver the prodrug inside the cell. According to the data from the present study, undamaged liposomes fuse with the cell membrane only 1.5–2 hours after binding to the cell surface, and then, the components of liposomal bilayer enter the cell separately. The study on the time course of plasma concentration in mice showed that the area under the curve of MTX generated upon intravenous injection of MTX-DG liposomes exceeded that of intact MTX 2.5-fold. These data suggested the advantage of using liposomal formulation to treat systemic manifestation of hematological malignancies. Indeed, the administration of MTX-DG liposomes to recipient mice bearing T-cell leukemic lymphoma using a dose-sparing regimen resulted in lower toxicity and retarded lymphoma growth rate as compared with MTX.

show abstract

mentioning

confidence: 99%

Liposomal formulation of a methotrexate lipophilic prodrug: assessment in tumor cells and mouse T-cell leukemic lymphoma

Алексеева¹,

Моисеева²,

Onishchenko³

et al. 2017

IJN

View full text Add to dashboard Cite

show abstract

“…8C). In addition, the Dox-free MTX-MagTSLs showed a little more cytotoxicity than free MTX due to the better membrane permeability [49,50]. Furthermore, compared with either single AMF or laser treating, the enhanced cytotoxicity of MTX-MagTSLs under DUAL-mode demonstrated that the simultaneous application of AMF and laser could lead to enhance cytotoxicity of Dox due to the acceleration of Dox release and uptake markedly (Fig.…”

Section: Accepted Manuscriptmentioning

confidence: 92%

Light/magnetic hyperthermia triggered drug released from multi-functional thermo-sensitive magnetoliposomes for precise cancer synergetic theranostics

Guo

Zhang

et al. 2018

Journal of Controlled Release

Self Cite

102

View full text Add to dashboard Cite

“…The folate receptor (FR) is overexpressed in many types of tumors . Binding folic acid (FolA) and FolA‐derivatives with very high affinity, the FR offers a prominent approach to selectively target FR‐positive cancer cells in targeted drug delivery approaches . A clinical phase I study for the treatment of advanced solid tumors currently assesses a small molecular drug conjugate (SMDC) of FolA with tubulysin…”

Section: Introductionmentioning

confidence: 99%

Sequence‐Defined Oligoamide Drug Conjugates of Pretubulysin and Methotrexate for Folate Receptor Targeted Cancer Therapy

Truebenbach

Gorges

Kuhn

et al. 2017

Macromolecular Bioscience

View full text Add to dashboard Cite

The conjugation of small molecule drugs to ligand containing carrier systems facilitates receptor targeted delivery. The folate receptor (FR) constitutes an ideal target for tumor selective therapy, being overexpressed on several tumor types. It can be targeted using the vitamin folic acid (FolA) or the structurally related drug methotrexate (MTX). Several sequence‐defined oligoamides with mono‐ and multivalent FolA or MTX ligands and an additional thiol conjugation site are synthesized via solid‐phase assisted synthesis. Their structure activity relationships are assessed in respect to dihydrofolate reductase inhibition, receptor mediated endocytosis, and cytotoxicity. Then, the tubulin‐binding agent pretubulysin (PT), a highly potent drug exhibiting antitumoral, antiangiogenic, and antimetastatic properties, is conjugated via an activated mercaptane derivative to the set of FR‐targeting oligoamides. In a combined PT/MTX cytotoxicity study in FR‐overexpressing KB and L1210 cells, a 2‐arm MTX‐PT construct or the 4‐arm analog displays the highest potency in the respective cell lines.

show abstract

Orthogonally Functionalized Nanoscale Micelles for Active Targeted Codelivery of Methotrexate and Mitomycin C with Synergistic Anticancer Effect

Cited by 58 publications

References 58 publications

Liposomal formulation of a methotrexate lipophilic prodrug: assessment in tumor cells and mouse T-cell leukemic lymphoma

Liposomal formulation of a methotrexate lipophilic prodrug: assessment in tumor cells and mouse T-cell leukemic lymphoma

Light/magnetic hyperthermia triggered drug released from multi-functional thermo-sensitive magnetoliposomes for precise cancer synergetic theranostics

Sequence‐Defined Oligoamide Drug Conjugates of Pretubulysin and Methotrexate for Folate Receptor Targeted Cancer Therapy

Contact Info

Product

Resources

About